Association between single nucleotide polymorphisms in AKT1 and the risk of prostate cancer in the Chinese Han population

Abstract

AKT1, also known as v-akt murine thymoma viral oncogene homolog 1, is involved in the regulation of cell-survival and anti-apoptotic activities, which may affect the pathogenesis of various cancers. However, the association between genetic variants of AKT1 and the risk of developing prostate cancer has not been investigated before. This study investigated the associations between three polymorphisms (rs1130214, rs3730358, and rs2494732) in AKT1 and the risk of development of prostate cancer in the Chinese Han population. Sequenom MassARRAY & iPLEX technology were used to genotype these polymorphisms in 493 Chinese Han patients with prostate cancer and 309 age-matched healthy individuals. Compared to the CC genotype of the rs3730358 polymorphism, the CT genotype of the same polymorphism was strongly associated with a decreased risk of prostate cancer (OR = 0.617, 95%CI = 0.390-0.976, P = 0.037). However, there was no significant difference between the allele frequency of the rs3730358 polymorphism and those of the other two polymorphisms (P > 0.05). Moreover, no significant difference was found in the haplotype analysis (P > 0.05). Our study found that the variant genotype CT of rs3730358 of AKT1 was associated with a decreased risk of prostate cancer, which suggested that this polymorphism could play an important role in the development of the disease.

Influence of a single-nucleotide polymorphism of AKT1 (rs2498796) and HEY2 (rs13328928) genes on the risk of endometrial cancer in women of the Republic of Tatarstan

“…Известно, что активированный ген AKT1 фосфорилирует нижестоящие субстраты, регулирующие рост клеток, метаболизм, апоптоз, ангиогенез и является онкогеном [7]. Установлено, что AKT1 ассоциирован со злокачественными новообразованиями щитовидной [8], молочной [9] и предстательной [10] желёз, также известна его роль в развитии рака желудка [11] и эндометрия [12]. Более того, доказан терапевтический потенциал ингибиторов AKT1 в подавлении роста злокачественных опухолей человека.…”